APG777 for Asthma
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of APG777 in adult participants with mild-to-moderate asthma.The duration of the study will be approximately 52 weeks (364 days) for each participant and will consist of a Screening Period, Treatment Period, and Follow-up Period.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications, but it requires that your asthma medications like inhaled corticosteroids or leukotriene receptor antagonists be stable for a certain period before starting the trial.
What makes the drug APG777 unique for treating asthma?
Are You a Good Fit for This Trial?
Adults with mild-to-moderate asthma are eligible for this study. Specific details about who can join or reasons why someone might be excluded were not provided, so interested individuals should contact the trial organizers for full eligibility criteria.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either APG777 or placebo as per protocol
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- APG777
Find a Clinic Near You
Who Is Running the Clinical Trial?
Apogee Therapeutics, Inc.
Lead Sponsor